Erich Pohanka

Erich Pohanka

Auto-generated profile, based on publicly available information

Erich Pohanka

Kepler University Hospital

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 1992 in Journal of Clinical Immunology
Verified
Journal Article
Closed access
PDF file
GZGerhard J. Zlabinger
Gerhard J. Zlabinger
KSKarl M. Stuhlmeier
Karl M. Stuhlmeier
REReinhard Eher
Reinhard Eher
SSSabine Schmaldienst
Sabine Schmaldienst
RKRenate Klauser
Renate Klauser
EPErich Pohanka
Erich Pohanka

14 September 2017 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
HPHerwig Pieringer
Herwig Pieringer
RHRainer Hintenberger
Rainer Hintenberger
EPErich Pohanka
Erich Pohanka
CSClemens Steinwender
Clemens Steinwender
JMJens Meier
Jens Meier
LSLorenz Stana-Hackenberg
Lorenz Stana-Hackenberg

1 January 1992 in Nephron
Verified
Journal Article
Closed access
OTOtto Traindl
Otto Traindl
SRSusan Reading
Susan Reading
MFMartina Franz
Martina Franz
BWBruno Watschinger
Bruno Watschinger
RKRenate Klauser
Renate Klauser
JKJosef Kovarik
Josef Kovarik
An increased incidence of hyperlipidemia places kidney graft recipients at increased risk for cardiovascular disease and may contribute to a decline in graft function. A study was undertaken to evaluate the safety and efficacy of lovastatin in these patients. Twelve kidney graft recipients with stable graft function and a cholesterol (chol) level over 250 mg/dl (6.46 mmol/l) were included. The lipid-lowering treatment consisted of 20 mg lovastatin daily, and all patients received immunosuppression with ciclosporin (CS) and prednisolone. Total chol decreased by 27% (300 +/- 56 to 219 +/- 28 mg/dl; 7.76 +/- 1.45 to 5.66 +/- 0.72 mmol/l; p < 0.01), LDL-chol by 35% (220 +/- 38 to 143 +/- 17 mg/dl; 5.69 +/- 0.98 to 3.70 +/- 0.44 mmol/l; p < 0.01) and triglycerides by 33% (207 +/- 127 to 138 +/- 56 mg/dl; 2.36 +/- 1.44 to 1.57 +/- 0.64 mmol/l; p < 0.05). HDL-chol increased by 10% (57 +/- 11 to 63 +/- 13 mg/dl; 1.47 +/- 0.28 to 1.63 +/- 0.34 mmol/l; NS). The ratio of total chol/HDL-chol, a generally accepted risk predictor of atherosclerosis, fell from 5.4 +/- 1.3 to 3.3 +/- 1.2, p < 0.01. Lipoprotein (a) [lp(a)], an independent risk predictor for atherosclerosis, was also evaluated at baseline and after 6 months of lovastatin treatment and showed a decrease of 39% (32.9 +/- 27.6 to 19.9 +/- 22.9 mg/dl; 0.85 +/- 0.71 to 0.51 +/- 0.59 mmol/l; p < 0.05). No adverse side effects were seen at this dosage, and hepatic and renal parameters remained unchanged.(ABSTRACT TRUNCATED AT 250 WORDS)

1 June 1991 in Clinical Transplantation
Verified
Journal Article
Closed access
OTO. Traindl
O. Traindl
SRS. Reading
S. Reading
MFM. Franz
M. Franz
EPE. Pohanka
E. Pohanka
JPJ. Pidlich
J. Pidlich
JKJ. Kovarik
J. Kovarik

1 January 2016 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
HPHerwig Pieringer
Herwig Pieringer
TBTobias Brummaier
Tobias Brummaier
BPBettina Piringer
Bettina Piringer
LSLorenz Stana-Hackenberg
Lorenz Stana-Hackenberg
AHAndreas Hartl
Andreas Hartl
MSMichael Schmid
Michael Schmid
Pieringer H, et al. J Korean Med Sci. 2016 Mar;31(3):382-388. http://dx.doi.org/10.3346/jkms.2016.31.3.382

1 January 2009
Verified
Book Chapter
Closed access
PDF file
AGAlexandra Geusau
Alexandra Geusau
EPErich Pohanka
Erich Pohanka